中草药

雷公藤及其有效成分治疗甲状腺相关眼病的临床及作用机制研究进展

PDF下载

中草药 | 综述 2026,57(10): 4008-4016

收起

中草药 |综述 2026 , 57 (10) : 4008 -4016

雷公藤及其有效成分治疗甲状腺相关眼病的临床及作用机制研究进展

全屏

屈之榆^1,2, 王菲^1,2, 王萍¹, 燕树勋^1,2,3

作者信息

通讯作者:

燕树勋

作者简介:

屈之榆: 屈之榆,博士研究生,住院医师,从事中西医结合临床防治内分泌疾病研究。E-mail:qzy961030@163.com

Research progress on Tripterygium wilfordii and its active ingredients in treatment of thyroid-associated ophthalmopathy

QU Zhiyu, WANG Fei, WANG Ping, YAN Shuxun

Affiliations

doi: 10.7501/j.issn.0253-2670.2026.10.028

文章导航

摘要

收起

甲状腺相关眼病（thyroid-associated ophthalmopathy，TAO）是一种与甲状腺功能障碍和自身免疫关系密切的眼眶炎性疾病，目前其发病机制尚未完全阐明，常规治疗存在不良反应大、耐药率高等问题。通过从理论、临床、机制、临床应用安全性、纳米剂型5个方面，系统综述雷公藤及其有效成分治疗TAO的研究进展。理论探析显示，雷公藤祛风除湿、舒筋通络、活血止痛与TAO肝郁气滞、脾虚湿困、瘀血阻络的病因病机相契合。临床研究证实，雷公藤单用或联合甲巯咪唑、强的松等药物，均可以较好地改善TAO患者的临床症状。机制研究进一步揭示，雷公藤及其有效成分治疗TAO的作用涉及抑制炎症和免疫反应，及抗纤维化作用等通路。临床应用安全性方面，通过调整剂量、剂型、炮制方式、配伍等方式可减轻其不良反应。在剂型改进方面，纳米递药系统通过靶向策略，显著提升雷公藤活性成分在病变部位的靶向富集与治疗选择性，是实现其临床增效减毒的关键途径。雷公藤及其有效成分在理论、临床、机制和安全性层面均显示出治疗TAO的良好潜力，结合现代纳米技术等剂型改良，有望为TAO的中医药防治提供具有前景的新策略。

关键词

甲状腺相关眼病 / 雷公藤 / 免疫抑制 / 抗炎 / 抗纤维化 / 减毒增效

Abstract

收起

Thyroid-associated ophthalmopathy (TAO) is an orbital inflammatory disease closely related to thyroid dysfunction and autoimmunity. The pathogenesis of TAO has not been fully elucidated yet. The conventional treatments have problems such as significant adverse reactions and high drug resistance rates. Through a systematic review of the research progress of Tripterygium wilfordii and its active components in the treatment of TAO from five aspects: theory, clinical practice, mechanism, clinical application safety, and nano-formulation, this paper explores the potential of Tripterygium wilfordii and its active components in treating TAO. The theoretical analysis shows that Tripterygium wilfordii’s functions of dispelling wind, removing dampness, relaxing muscles and tendons, and promoting blood circulation and relieving pain are in line with the pathogenesis of TAO, which involves liver depression, spleen deficiency, and blood stasis blocking the meridians. Clinical studies have confirmed that Tripterygium wilfordii alone or in combination with methimazole, prednisone, etc., can effectively improve the clinical symptoms of TAO patients. Mechanism research further reveals that the effects of Tripterygium wilfordii and its active components in treating TAO involve inhibiting inflammatory and immune responses, as well as anti-fibrotic effects, etc. In terms of clinical application safety, adverse reactions can be alleviated by adjusting dosage, formulation, processing methods, and compatibility. In terms of formulation improvement, the nano-delivery system, through targeted strategies, significantly enhances the targeted enrichment and therapeutic selectivity of active components of Tripterygium wilfordii in the lesion site, which is a key approach to achieving clinical enhancement of efficacy and reduction of toxicity. In summary, Tripterygium wilfordii and its active components show good potential in treating TAO in terms of theory, clinical practice, mechanism, and safety. Combined with modern nanotechnology and other formulation improvements, this may provide a promising new strategy for the traditional Chinese medicine prevention and treatment of TAO.

Key words

thyroid-associated ophthalmopathy / Tripterygium wilfordii Hook F. / immunosuppression / anti-inflammatory / anti-fibrotic / synergistic

引用本文

屈之榆, 王菲, 王萍, 燕树勋. 雷公藤及其有效成分治疗甲状腺相关眼病的临床及作用机制研究进展. 中草药, 2026 , 57 (10) : 4008 -4016 . DOI: 10.7501/j.issn.0253-2670.2026.10.028

QU Zhiyu, WANG Fei, WANG Ping, YAN Shuxun. Research progress on Tripterygium wilfordii and its active ingredients in treatment of thyroid-associated ophthalmopathy[J]. Chinese Traditional and Herbal Drugs, 2026 , 57 (10) : 4008 -4016 . DOI: 10.7501/j.issn.0253-2670.2026.10.028

基金

收起

中原英才计划-中原医疗卫生领军人才 (FCZZX038); 河南省自然科学基金资助项目 (252300420619,262300421584,262300422236); 中华中医药学会临床医案专项课题 (45); 河南省卫健委国家中医药传承创新中心联合共建科研专项 (2024ZXZX1175); 郑州市医疗卫生领域科技创新指导计划 (2024YLZDJH080,2025YLZDJH313)

参考文献

收起

文献

收起

参考文献引证文献

排序方式：

Ferrari S M, Paparo S R, Ragusa F, et al. Chemokines in thyroid autoimmunity [J]. Best Pract Res Clin Endocrinol Metab, 2023, 37(2): 101773.
Hoang T D, Stocker D J, Chou E L, et al. 2022 update on clinical management of Graves disease and thyroid eye disease [J]. Endocrinol Metab Clin N Am, 2022, 51(2): 287-304.
李阳. 吗替麦考酚酯联合甲强龙在治疗活动性中重度甲状腺相关眼病中的临床疗效分析[D]. 大连: 大连医科大学, 2023.
Antonelli A, Fallahi P, Elia G, et al. Graves’ disease: Clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy [J]. Best Pract Res Clin Endocrinol Metab, 2020, 34(1): 101388.
李会敏, 魏军平, 韦茂英, 等. 基于“玄府郁闭-眼部微循环障碍”探讨甲状腺相关眼病[J]. 中华中医药学刊, 2023, 41(5): 107-110.
Song C Y, Xu Y G, Lu Y Q. Use of Tripterygium wilfordii Hook F for immune-mediated inflammatory diseases: Progress and future prospects [J]. J Zhejiang Univ Sci B, 2020, 21(4): 280-290.
陈亦霞, 罗悦, 吴宁玲. 雷公藤在眼科的药理作用及临床应用现状[J]. 中国中医眼科杂志, 2023, 33(2): 185-188.
刘祥秀, 李红, 孔德明. 瘿病中医名词术语规范化研究探讨[J]. 贵阳中医学院学报, 2015, 37(3): 5-8.
孙文英, 师宜鹏, 张丰, 等. 眼珠突高源流考略[J]. 中国中医眼科杂志, 2023, 33(12): 1150-1154.
朱明悦, 邵迎新. 导师从痰瘀论治甲状腺相关眼病经验[J]. 云南中医中药杂志, 2023, 44(4): 117-119.
高伟, 刘梦婷, 程琪庆, 等. 雷公藤的本草考证[J]. 世界中医药, 2012, 7(6): 560-562.
赵沛东, 郭闫闫, 任相阁, 等. 雷公藤及其活性成分治疗糖尿病肾病的作用机制研究进展[J]. 中国实验方剂学杂志, 2026, 32(7): 352-362.
姜淼, 张海波, 丁樱. 雷公藤多苷药理作用及临床应用研究进展[J]. 中华中医药学刊, 2021, 39(3): 59-63.
Liu X W, Gao C H, Liu X L, et al. Efficacy and safety of Tripterygium glycosides for Graves ophthalmopathy: A systematic review and Meta-analysis [J]. Medicine, 2019, 98(50): e18242.
姚骥如, 孙莹, 罗顺葵, 等. 雷公藤多苷的临床应用进展[J]. 中国新药与临床杂志, 2010, 29(3): 179-182.
周培培. 雷公藤制剂治疗甲状腺相关性眼病的Meta分析[D]. 武汉: 湖北中医药大学, 2020.
王晓敏, 王晓玲. 雷公藤多甙治疗甲亢突眼的临床研究[J]. 江苏中医, 1995, 16(10): 41-42.
王坚, 王扬天, 邵加庆, 等. Graves眼病部分免疫抑制剂疗效探讨[J]. 中华内科杂志, 2004, 43(2): 125-127.
王坚, 王扬天, 邵加庆, 等. Graves眼病免疫治疗探讨[J]. 西安交通大学学报: 医学版, 2003, 24(2): F002.
张建飞, 孔园珍, 潘红珍. 雷公藤多甙治疗甲亢突眼临床疗效观察[J]. 中国农村卫生事业管理, 2014, 34(6): 761-762.
罗嘉, 黄佳, 叶茂. 雷公藤多甙联合糖皮质激素治疗Graves眼病的疗效观察[J]. 实用医院临床杂志, 2015, 12(5): 174-176.
文雅雅, 傅洁, 周卫东. 雷公藤多苷联合糖皮质激素治疗甲状腺相关性眼病疗效的Meta分析[J]. 中医临床研究, 2021, 13(34): 140-144.
何晓惠, 孔德明. 雷公藤多甙联合小剂量强的松治疗Graves眼病23例疗效观察[J]. 新中医, 2010, 42(8): 65-66.
叶小珍. 霉酚酸酯或雷公藤多甙靶向治疗活动性中重度甲状腺相关性眼病的疗效性和安全性的随机对照研究[D]. 广州: 南方医科大学, 2017.
马雏凤, 王永胜. 雷公藤多甙联合甲巯咪唑治疗甲亢突眼的临床效果[J]. 世界最新医学信息文摘: 连续型电子期刊, 2016, 16(75): 104.
许建平, 许晨, 陈俊, 等. Graves眼病外周血细胞因子水平与雷公藤多苷干预的影响[J]. 中国中药杂志, 2014, 39(3): 544-547.
聂梅. 雷公藤多苷联合甲巯咪唑、醋酸泼尼松片治疗甲亢突眼患者的疗效评价[J]. 黑龙江中医药, 2021, 50(3): 162-163.
常昕昱. 雷公藤多苷联合他巴唑与强的松治疗甲亢突眼的效果观察[J]. 中国医药指南, 2019, 17(21): 167-168.
林豫路. 雷公藤多苷联合他巴唑与强的松治疗甲亢突眼122例[J]. 中国药物经济学, 2012, 7(5): 119-120.
吴健停. 雷公藤多苷联合他巴唑强的松治疗甲亢突眼临床分析[J]. 当代医学, 2012, 18(22): 79-80.
李小利, 马涛. 甲亢突眼征患者应用雷公藤多甙联合他巴唑与强的松治疗的临床效果[J]. 临床医学研究与实践, 2017, 2(22): 75-76.
敖文. 他巴唑与强的松、雷公藤多甙联用治疗甲亢突眼征患者的疗效观察[J]. 中国民康医学, 2015, 27(13): 95-96.
廖学东. 他巴唑强的松与雷公藤多甙联用治疗甲亢突眼的疗效观察[J]. 中国保健营养, 2012, 22(10): 1514-1515.
张志宇, 王俊宏. 雷公藤多甙联合他巴唑强的松治疗甲亢突眼[J]. 医药论坛杂志, 2010, 31(8): 110-111.
迟鹏威. 雷公藤多苷联合甲巯咪唑、强的松治疗甲亢突眼的临床分析[J]. 北方药学, 2017, 14(9): 34-35.
曹萌萌, 孙良阁. 生长抑素、雷公藤多甙联合糖皮质激素治疗Graves眼病的临床分析[J]. 河南医学研究, 2013, 22(3): 340-342.
岳筱, 王妍妍, 杨阳, 等. 糖皮质激素联合生长抑素、雷公藤多苷治疗甲状腺相关眼病临床疗效及安全性分析[J]. 河南医学研究, 2017, 26(1): 31-33.
田梅玲. 雷公藤多甙联合⁹⁹锝-亚甲基二膦酸盐治疗甲状腺相关眼病疗效观察[J]. 实用中西医结合临床, 2020, 20(5): 17-18.
韩冬, 陆从庆, 徐同道, 等. 云克联合雷公藤多苷对Graves眼病眼球球后软组织周长及面积的影响[J]. 贵州医药, 2014, 38(9): 809-810.
胡青, 杨美东. 雷公藤多苷联合泼尼松与环磷酰胺治疗甲亢突眼的效果[J]. 中外医学研究, 2024, 22(36): 17-20.
刘博. 中医药治疗Graves眼病的中医证型及用药规律分析[D]. 沈阳: 辽宁中医药大学, 2020.
苟晓燕, 程刚. 西替利嗪联合雷公藤多苷治疗甲状腺相关性眼病24例[J]. 中国药业, 2012, 21(18): 85-86.
王伟, 杨宾, 孙浩杰, 等. ¹³¹I联合雷公藤多甙治疗Graves眼病[J]. 中华核医学杂志, 2004, 24(3): 166-167.
薛峰, 张文娟. 应用雷公藤多甙治疗甲亢突眼的症状转归分析[J]. 世界最新医学信息文摘, 2019, 19(46): 214.
Wang F, Li C Y, Li S X, et al. Selenium and thyroid diseases [J]. Front Endocrinol, 2023, 14: 1133000.
Neag E J, Smith T J. 2021 update on thyroid-associated ophthalmopathy [J]. J Endocrinol Investig, 2022, 45(2): 235-259.
Bartalena L, Piantanida E, Gallo D, et al. Epidemiology, natural history, risk factors, and prevention of Graves’ orbitopathy [J]. Front Endocrinol, 2020, 11: 615993.
燕树勋, 陈如泉. 雷公藤甲素对球后成纤维细胞的影响[J]. 现代中西医结合杂志, 2004, 13(11): 1432-1433.
Taylor P N, Zhang L, Lee R W J, et al. New insights into the pathogenesis and nonsurgical management of Graves orbitopathy [J]. Nat Rev Endocrinol, 2020, 16(2): 104-116.
Sun A Q, Ye H J, Xu Z H, et al. Serelaxin alleviates fibrosis in thyroid-associated ophthalmopathy via the Notch pathway [J]. Int J Mol Sci, 2023, 24(9): 8356.
黄慧. Graves眼病患者检测血清VEGF、HA、bFGF、sICAM-1的临床意义及免疫治疗研究[D]. 南京: 南京大学, 2011.
王萍, 符宇, 蒋敏敏, 等. Th17和Treg细胞及其平衡对甲状腺相关眼病的影响[J]. 国际眼科杂志, 2022, 22(7): 1137-1142.
王欣之, 农程, 江振洲, 等. 雷公藤甲素对脾脏Th17/ Treg细胞的影响[J]. 中国中药杂志, 2019, 44(15): 3330-3334.
燕树勋, 王颖. 雷公藤甲素对IFN-γ刺激后人眼球后成纤维细胞的影响[J]. 眼科新进展, 2009, 29(6): 416-419.
陈如泉, 燕树勋, 华川, 等. 雷公藤甲素对自身免疫性甲状腺病及相关眼病作用机制研究[Z]. 武汉: 湖北省中医院, 2007.
Cui X J, Wang F T, Liu C. A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves’ orbitopathy [J]. Front Immunol, 2023, 14: 1062045.
Rotondo Dottore G, Torregrossa L, Caturegli P, et al. Association of T and B cells infiltrating orbital tissues with clinical features of Graves orbitopathy [J]. JAMA Ophthalmol, 2018, 136(6): 613.
Fang S J, Huang Y Z, Wang N J, et al. Insights into local orbital immunity: Evidence for the involvement of the Th17 cell pathway in thyroid-associated ophthalmopathy [J]. J Clin Endocrinol Metab, 2019, 104(5): 1697-1711.
Li H, Yuan Y F, Zhang Y L, et al. Celastrol inhibits IL-1β-induced inflammation in orbital fibroblasts through the suppression of NF-κB activity [J]. Mol Med Rep, 2016, 14(3): 2799-2806.
Yu H, Lin L B, Zhang Z Q, et al. Targeting NF-κB pathway for the therapy of diseases: Mechanism and clinical study [J]. Signal Transduct Target Ther, 2020, 5: 209.
张国玉. 基于网络药理学的雷公藤干预Graves眼病潜在靶点预测及作用机制分析[J]. 河南中医, 2022, 42(6): 866-872.
陈曦, 李洪锦, 迮侃, 等. 雷公藤抗炎作用相关信号转导机制研究进展[J]. 中华中医药学刊, 2021, 39(5): 184-187.
Chiu H I, Wu S B, Tsai C C. The role of fibrogenesis and extracellular matrix proteins in the pathogenesis of Graves’ ophthalmopathy [J]. Int J Mol Sci, 2024, 25(6): 3288.
Starkey K J, Janezic A, Jones G, et al. Adipose thyrotrophin receptor expression is elevated in Graves’ and thyroid eye diseases ex vivo and indicates adipogenesis in progress in vivo [J]. J Mol Endocrinol, 2003, 30(3): 369-380.
Valyasevi R W, Erickson D Z, Harteneck D A, et al. Differentiation of human orbital preadipocyte fibroblasts induces expression of functional thyrotropin receptor 1[J]. J Clin Endocrinol Metab, 1999, 84(7): 2557-2562.
Sorisky A, Pardasani D, Gagnon A, et al. Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture [J]. J Clin Endocrinol Metab, 1996, 81(9): 3428-3431.
Prabhakar B S, Bahn R S, Smith T J. Current perspective on the pathogenesis of Graves’ disease and ophthalmopathy [J]. Endocr Rev, 2003, 24(6): 802-835.
Jiang M M, Wang P, Yu D D, et al. Network pharmacology and experiments verify the effect of triptolide on extraocular muscle fibrosis [J]. PLoS One, 2025, 20(11): e0336487.
Lai K B, Li Y Q, Li L H, et al. Intravitreal injection of triptolide attenuates subretinal fibrosis in laser-induced murine model [J]. Phytomedicine, 2021, 93: 153747.
李雨蔓, 陈世伟, 夏旭东, 等. 2004—2019年河南省雷公藤制剂不良反应分析[J]. 现代药物与临床, 2020, 35(5): 988-994.
肖丽涓, 毛泽玲, 黄枚, 等. 3种炮制方法对雷公藤肝肾毒性的减毒作用[J]. 福建中医药, 2024, 55(1): 35-37.
赵明洪, 卢天明, 刘莉, 等. 甘草减轻雷公藤多苷片所致肝损伤的作用机制[J]. 中国实验方剂学杂志, 2023, 29(5): 24-31.
陈文娟, 吴晶金. 雷公藤毒性及中药配伍减毒研究进展[J]. 中成药, 2023, 45(2): 499-503.
宋玲玲, 王君明, 弓明珠, 等. 金钱草降低雷公藤致小鼠肾毒性的实验研究[J]. 中华中医药学刊, 2023, 41(4): 50-54.
张维钲, 祁晓鸣, 左玉芹, 等. 黄芪-当归配伍调节Keap1/Nrf2/PGC-1α信号抑制雷公藤甲素肝脏毒性的作用及机制[J]. 中国中药杂志, 2023, 48(23): 6378-6386.
肖芳, 管咏梅, 陶玲, 等. 雷公藤配伍白芍对雷公藤提取物透皮吸收的影响[J]. 中国实验方剂学杂志, 2018, 24(22): 34-39.
陈琪, 周静威, 孙满强, 等. 地黄水提物减轻雷公藤甲素所致肝脏氧化应激损伤的实验研究[J]. 世界中西医结合杂志, 2020, 15(12): 2241-2245.
Li X J, Jiang Z Z, Zhang L Y. Triptolide: Progress on research in pharmacodynamics and toxicology [J]. J Ethnopharmacol, 2014, 155(1): 67-79.
Wen Y, Meng W S. Recent in vivo evidences of particle-based delivery of small-interfering RNA (siRNA) into solid tumors [J]. J Pharm Innov, 2014, 9(2): 158-173.
Maeda H, Nakamura H, Fang J. The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo [J]. Adv Drug Deliv Rev, 2013, 65(1): 71-79.
Zrazhevskiy P, Sena M, Gao X H. Designing multifunctional quantum dots for bioimaging, detection, and drug delivery [J]. Chem Soc Rev, 2010, 39(11): 4326-4354.
Wang Y C, Liu X W, Wang X M, et al. Redox-responsive self-assembly PEG nanoparticle enhanced triptolide for efficient antitumor treatment [J]. Sci Rep, 2018, 8: 12968.
Sun R, Dai J Y, Ling M J, et al. Delivery of triptolide: A combination of traditional Chinese medicine and nanomedicine [J]. J Nanobiotechnol, 2022, 20(1): 194.
He P, Sun J, Tan J, et al. From physicochemical constraints to clinical prospects of celastrol: Challenges and nano delivery strategies [J]. Int J Nanomed, 2025, 20: 10907-10931.
Tiwari P, Yadav K, Shukla R P, et al. Surface modification strategies in translocating nano-vesicles across different barriers and the role of bio-vesicles in improving anticancer therapy [J]. J Control Release, 2023, 363: 290-348.
Xu Y N, Fourniols T, Labrak Y, et al. Surface modification of lipid-based nanoparticles [J]. ACS Nano, 2022, 16(5): 7168-7196.
Zhao Z M, Ukidve A, Kim J, et al. Targeting strategies for tissue-specific drug delivery [J]. Cell, 2020, 181(1): 151-167.
Xu L Y, Chen H B, Xu H B, et al. Anti-tumour and immuno-modulation effects of triptolide-loaded polymeric micelles [J]. Eur J Pharm Biopharm, 2008, 70(3): 741-748.
Mei Z N, Li X K, Wu Q R, et al. The research on the anti-inflammatory activity and hepatotoxicity of triptolide-loaded solid lipid nanoparticle [J]. Pharmacol Res, 2005, 51(4): 345-351.
Yu L, Wang Z J, Mo Z M, et al. Synergetic delivery of triptolide and Ce6 with light-activatable liposomes for efficient hepatocellular carcinoma therapy [J]. Acta Pharm Sin B, 2021, 11(7): 2004-2015.
Chen G, Hao B H, Ju D H, et al. Pharmacokinetic and pharmacodynamic study of triptolide-loaded liposome hydrogel patch under microneedles on rats with collagen-induced arthritis [J]. Acta Pharm Sin B, 2015, 5(6): 569-576.
Zhang X W, Zhang T P, Zhou X T, et al. Enhancement of oral bioavailability of tripterine through lipid nanospheres: Preparation, characterization, and absorption evaluation [J]. J Pharm Sci, 2014, 103(6): 1711-1719.
Liu M X, Dong J, Yang Y J, et al. Effect of poly(D,L-lactic acid) nanoparticles as triptolide carrier on abating rats renal toxicity by NMR-based metabolic analysis [J]. J Nanosci Nanotechnol, 2008, 8(7): 3493-3499.
Fan N, Zhao J, Zhao W, et al. Celastrol-loaded lactosylated albumin nanoparticles attenuate hepatic steatosis in non-alcoholic fatty liver disease [J]. J Control Release, 2022, 347: 44-54.
Xu C, Song R J, Lu P, et al. pH-triggered charge-reversal and redox-sensitive drug-release polymer micelles codeliver doxorubicin and triptolide for prostate tumor therapy [J]. Int J Nanomedicine, 2018, 13: 7229-7249.
Zhang Y Q, Shen Y, Liao M M, et al. Galactosylated chitosan triptolide nanoparticles for overcoming hepatocellular carcinoma: Enhanced therapeutic efficacy, low toxicity, and validated network regulatory mechanisms [J]. Nanomed Nanotechnol Biol Med, 2019, 15(1): 86-97.

2026年第57卷第10期

PDF下载

引用本文

BibTeX

文章信息

doi: 10.7501/j.issn.0253-2670.2026.10.028

接收时间：2025-11-11
首发时间：2026-09-09

补充材料

相关文章

文章信息

作者

出版历史

收稿日期：2025-11-11

基金

作者信息

参考文献

分享链接

https://castjournals.cast.org.cn/joweb/zcy/CN/10.7501/j.issn.0253-2670.2026.10.028

分享至

全文二维码

扫描看全文

引用本文

BibTeX

本文的引用情况

2种不同金属材料的力学参数

科 Family	属数 Number of genus	种数 Number of species	占总种数比例 Percentage of total species (%)	属 Genus	种数 Number of species	占总种数比例 Percentage of total species (%)
鹅膏菌科Amanitaceae	2	11	5.26	鹅膏菌属 Amanita	10	4.78
小菇科 Mycenaceae	2	12	5.74	丝盖伞属 Inocybe	5	2.39
多孔菌科 Polyporaceae	8	14	6.70	蜡蘑属 Laccaria	5	2.39
红菇科 Russulaceae	3	23	11.00	小皮伞属 Marasmius	6	2.87
				小菇属 Mycena	11	5.26
				光柄菇属 Pluteus	5	2.39
				红菇属 Russula	17	8.13
				栓菌属 Trametes	5	2.39

关闭全屏

BibTeX
EndNote
RefWorks
TxT